Increased Plasma Concentrations of Unbound SN-38, the Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal Failure

Removal of Protein-Bound Uraemic Toxins by Haemodialysis

(2013) Toshimitsu Niwa   BLOOD PURIFICATION

Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide

(2013) E. I. Zimmerman et al.   CLINICAL CANCER RESEARCH

Pharmacokinetic Alteration of 99mTc-MAG3 using Serum Protein Binding Displacement Method

(2013) Kodai Nishi et al.   NUCLEAR MEDICINE AND BIOLOGY

Direct Inhibition and Down-regulation by Uremic Plasma Components of Hepatic Uptake Transporter for SN-38, an Active Metabolite of Irinotecan, in Humans

(2013) Ken-ichi Fujita et al.   PHARMACEUTICAL RESEARCH

Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation

(2012) Ping Zhao et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Plasma protein carbonylation in chronic uremia

(2011) Barbara Pavone et al.   JOURNAL OF NEPHROLOGY

Delayed Elimination of SN-38 in Cancer Patients with Severe Renal Failure

(2010) K.-i. Fujita et al.   DRUG METABOLISM AND DISPOSITION

The effect ofSLCO1B1polymorphism on repaglinide pharmacokinetics persists over a wide dose range

(2008) Annikka Kalliokoski et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY